The effect of anti platelet therapy on amputation-free survival following lower limb peripheral endovascular intervention for patients with peripheral arterial disease.

Aneurin Bevan University Health Board0 个研究点目标入组 516 人开始时间: 2018年4月10日最近更新: 2021年5月3日

适应症

试验速览

暂无简介。

•Patients undergoing primary angioplasty or stenting with bare metal or drug-eluting stents of the infra-renal aorta; common or external iliac arteries; common, superficial or deep femoral artery; popliteal artery; tibio-peroneal trunk; anterior or posterior tibial artery or peroneal artery or any pedal artery for stenotic or occlusive peripheral arterial disease
•Patients undergoing primary angioplasty or stenting of a stenosis in a surgical bypass graft running between two of the included arteries mentioned above
•Patients already included in the study by virtue of treatment of the contralateral limb, who subsequently undergo endovascular therapy to the other leg

•Patients undergoing treatment for aneurysmal disease, or for a complication of treatment of aneurysmal disease
•Lesions treated with covered stent grafts
•Patients already recruited into the study and undergoing repeated endovascular therapy to the same limb
•Patients undergoing treatment proximal to the infra-renal aorta, to the upper limb, head and next vessels, mesenteric or renal vessels
•Patients undergoing diagnostic angiogram only, with no attempt made to perform angioplasty
•Patients undergoing intra-arterial embolectomy, thrombectomy or thrombolysis, other than those where this is commenced immediately following primary angioplasty or stenting in order to treat a complication.
•Venous procedures (e.g. stenting of veins following DVT)
•Angioplasty or stenting of arterio-venous fistulas
•Treatment of arterio-venous malformations
•Patients receiving therapeutic anticoagulation in the form of therapeutic dose low molecular weight heparin; or warfarin with a target international normalised ratio of 2.0 or more; or a direct oral anticoagulant such as apixaban, dabigatran or rivaroxaban at therapeutic dosage.

发起方